Form 4: Nautilus Biotechnology Director Melissa Epperly Granted 45,000 Stock Options

Nautilus Biotechnology, Inc. Director Melissa B. Epperly was granted 45,000 stock options with an exercise price of $0.6951, vesting monthly over one year.

Summary

• Melissa B. Epperly, a Director of Nautilus Biotechnology, Inc. (NAUT), was granted 45,000 stock options.
• The options have an exercise price of $0.6951 per share.
• The grant date for these options was June 23, 2025.
• The options become exercisable on June 23, 2025, and expire on June 23, 2035.
• Vesting occurs monthly, with one-twelfth (1/12th) of the shares vesting each month following the grant date, contingent on Epperly's continuous status as a 'Service Provider' under the Issuer's 2021 Equity Incentive Plan.
• Following this transaction, Melissa B. Epperly beneficially owns 45,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While a Form 4 is a routine disclosure, the grant of options to a director is a positive signal of continued commitment and alignment of interests, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long window for potential value realization.

Negatives

• The exercise price of $0.6951 is relatively low, suggesting the options were granted at or near the current market price, which is typical for compensation but doesn't indicate an immediate premium.

Risks

• The value of the stock options is subject to the future performance of Nautilus Biotechnology's common stock; if the stock price does not rise above the exercise price, the options may expire worthless.
• Vesting is contingent on continuous service, meaning the options could be forfeited if the director's service terminates before full vesting.

Future Outlook

The stock options granted to Director Melissa B. Epperly are subject to a monthly vesting schedule over a one-year period, contingent on her continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan. The options have an expiration date of June 23, 2035, providing a long-term incentive.

Industry Context

This Form 4 filing details a routine compensation event for a director within the biotechnology sector. Granting stock options is a common practice across industries, including biotech, to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector.
• The vesting schedule (monthly over one year) is a common approach to ensure continued service and align incentives over a reasonable period, comparable to similar grants observed in companies like Illumina (ILMN) or Pacific Biosciences of California (PACB) for their non-employee directors, though specific grant sizes and exercise prices vary based on company size, stock price, and compensation philosophy.

Related Party Transactions

• The stock option grant to Melissa B. Epperly, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's interests with shareholders, potentially incentivizing decisions that enhance long-term stock value. However, it also represents potential future dilution if options are exercised.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• Monthly vesting of the 45,000 stock options will occur over the next 12 months, contingent on Melissa B. Epperly's continuous service.

Key Dates

Recommendation

Keywords

Nautilus Biotechnology, NAUT, SEC Form 4, Stock Option Grant, Director Compensation, Equity Incentive Plan, Insider Transaction, Derivative Securities, Vesting Schedule